Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2023-11-30 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the company's management participation in upcoming investor meetings. It references compliance with SEBI regulations and explicitly states that no unpublished price sensitive information will be shared. The document length is only 1220 characters, indicating it is a brief announcement rather than a detailed report. There are no financial statements, detailed financial data, or comprehensive analysis present. This fits the profile of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-11-30 English
Updates
Major Shareholding Notification Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the submission of an application for reclassification of a shareholder category under SEBI Listing Regulations. It references regulatory provisions and is an announcement of a corporate action related to shareholding categories. The document is short (1484 characters) and does not contain financial statements, audit information, or detailed report content. It is not a report itself but an official notification of a change in shareholding classification. This fits best under Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or classification.
2023-11-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter dated November 21, 2023, addressed to stock exchanges regarding the company's participation in an investor conference. It references a previous intimation letter and provides an update on the schedule of the conference and investor meetings. The content is an announcement about management's participation in an investor event and does not contain financial data, detailed presentations, or reports. It is a regulatory disclosure under SEBI regulations about investor relations activities. The document length is short (1853 characters), and it serves as an update or notification rather than a full report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about the company's management meeting with investors on specific dates. It explicitly states it is pursuant to a regulatory requirement (SEBI Listing Obligations) and contains no financial data or detailed report content. The document is an announcement of an upcoming investor meeting, not a report or transcript. It is brief (1233 characters) and serves as a regulatory disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2023-11-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the company's management participation in an upcoming investor conference. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document explicitly states that no unpublished price sensitive information will be shared and is intended for information and records. There are no financial statements, detailed financial data, or report content included. The document length is only 1388 characters, indicating it is a brief announcement rather than a full report or transcript. Therefore, this fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-11-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an investor conference call for the second quarter of fiscal year 2024 (Q2FY24) for Mankind Pharma Limited. It includes management commentary on financial performance, business updates, and a Q&A session. The text explicitly states it is a transcript of the earnings conference call, with detailed financial figures, management discussion, and forward-looking statements. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is not merely an announcement or summary but contains the full transcript of the call, including management remarks and Q&A. Therefore, the correct classification is CT with high confidence.
2023-11-07 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.